Premium
Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis in HIV/AIDS Patients in India—A Pilot Pharmacokinetic Study
Author(s) -
Jadhav Manoj,
Jadhav Priyanka,
Shinde Vishal,
Kadam Prashant,
Kshirsagar Nilima
Publication year - 2013
Publication title -
clinical pharmacology in drug development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 22
eISSN - 2160-7648
pISSN - 2160-763X
DOI - 10.1002/cpdd.6
Subject(s) - pharmacokinetics , medicine , amphotericin b , cryptococcal meningitis , nephrotoxicity , meningitis , fluconazole , pharmacology , human immunodeficiency virus (hiv) , gastroenterology , antifungal , surgery , toxicity , immunology , viral disease , dermatology
Abstract The liposomal formulation of amphotericin B greatly reduces side effects like nephrotoxicity. The present pilot study describes the pharmacokinetic characteristics of liposomal Amp B given to eight patients of cryptococcal meningitis with HIV/AIDS at a dose of 1 and 3 mg/kg/day. We observed that the pharmacokinetic parameters namely AUC, C max , CL, Vd, and half‐life were not proportionate with 1 and 3 mg/kg/day dose of Fungiosme™. With 1 and 3 mg/kg/day dose the mean C max was found to be 626.54 ± 39.26 and 1049.90 ± 742.75 ng/mL, respectively. In conclusion, liposomal Amp B was observed to be safe and efficacious in the treatment of cryptococcal meningitis in HIV/AIDS patients, however, a pharmacokinetics study with larger cohort of patients of cryptococcal meningitis in HIV AIDS is warranted.